UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q/A
(Amendment No. 1)
x | Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 |
|
|
o | Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
Commission file number 001-15070
REGENERX BIOPHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware |
| 52-1253406 |
(State of Incorporation) |
| (IRS Employer I.D. Number) |
|
|
|
3 Bethesda Metro Center
Suite 630
Bethesda, Maryland 20814
(Address of Principal Executive Offices)
(301) 280-1992
(Registrant’s Telephone Number, Including Area Code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer o |
| Accelerated filer o |
|
|
|
Non-accelerated filer o |
| Smaller reporting company x |
(Do not check if a smaller reporting company) |
|
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
|
| Yes | o | No x |
51,553,527 shares of RegeneRx Biopharmaceuticals, Inc. Common Stock, par value $0.001 per share, were outstanding as of May 6, 2008.
EXPLANATORY NOTE
This Amendment No. 1 to our Quarterly Report on Form 10-Q for the period ended March 31, 2008 (the “Report”), filed on May 15, 2008, is being filed solely to amend exhibits 31.1 and 31.2, which inadvertently omitted certain required language. These amendments speak as of the original filing date of the Report. No other changes have been made to the Report.
2
Item 6. Exhibits
Exhibit No. |
| Description of Exhibit |
| Reference |
|
|
|
|
|
31.1 & 31.2 |
| Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| Filed herewith |
3
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
| RegeneRx Biopharmaceuticals, Inc. | |
|
|
|
|
| (Registrant) |
|
|
|
|
| |
|
|
|
|
| |
Date: | July 31, 2008 |
| By: | /s/J.J. Finkelstein | |
|
|
|
| J.J. Finkelstein | |
|
|
|
| President and Chief Executive Officer | |
|
|
|
| (duly authorized officer) | |
|
|
|
|
| |
|
|
|
|
| |
|
|
| By: | /s/C. Neil Lyons | |
|
|
|
| C. Neil Lyons | |
|
|
|
| Chief Financial Officer | |
|
|
|
| (principal financial officer) | |
4